Cargando…

Mineralocorticoid Receptor Antagonist Use and Hard Renal Outcomes in Real-World Patients With Chronic Kidney Disease

Real-world evidence about mineralocorticoid receptor antagonist (MRA) use has been limited in chronic kidney disease, particularly regarding its association with hard renal outcomes. METHODS: In this retrospective cohort study, adult chronic kidney disease outpatients referred to the department of n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oka, Tatsufumi, Sakaguchi, Yusuke, Hattori, Koki, Asahina, Yuta, Kajimoto, Sachio, Doi, Yohei, Kaimori, Jun-Ya, Isaka, Yoshitaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8823908/ https://www.ncbi.nlm.nih.gov/pubmed/35026955 http://dx.doi.org/10.1161/HYPERTENSIONAHA.121.18360

Ejemplares similares

Time-updated anion gap and cardiovascular events in advanced chronic kidney disease: a cohort study
por: Asahina, Yuta, et al.
Publicado: (2021)

Diagnosing metabolic acidosis in chronic kidney disease: importance of blood pH and serum anion gap
por: Kaimori, Jun-Ya, et al.
Publicado: (2022)

Low-grade proteinuria and atherosclerotic cardiovascular disease: A transition study of patients with diabetic kidney disease
por: Yamaguchi, Satoshi, et al.
Publicado: (2022)

A heterozygous LAMA5 variant may contribute to slowly progressive, vinculin-enhanced familial FSGS and pulmonary defects
por: Kaimori, Jun-Ya, et al.
Publicado: (2022)

Hidden Hypocalcemia as a Risk Factor for Cardiovascular Events and All-Cause Mortality among Patients Undergoing Incident Hemodialysis
por: Yamaguchi, Satoshi, et al.
Publicado: (2020)

Alkali therapy for prevention of acute kidney injury in rhabdomyolysis
por: Kaimori, Jun-Ya, et al.
Publicado: (2022)

Plant-Dominant Low Protein Diet: A Potential Alternative Dietary Practice for Patients with Chronic Kidney Disease
por: Sakaguchi, Yusuke, et al.
Publicado: (2023)

Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
por: Tezuka, Yuta, et al.
Publicado: (2021)

Variability in estimated glomerular filtration rate and patients' outcomes in a real‐world heart failure population
por: Oka, Tatsufumi, et al.
Publicado: (2021)

Serum phosphate levels modify the impact of parathyroid hormone levels on renal outcomes in kidney transplant recipients
por: Doi, Yohei, et al.
Publicado: (2020)

Real-world evidence for steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease
por: Folkerts, Kerstin, et al.
Publicado: (2022)

SAT-561 Effects of Mineralocorticoid Receptor Antagonists on Primary Aldosteronism Screening
por: Tezuka, Yuta, et al.
Publicado: (2020)

Renoprotection by long‐term low‐dose tolvaptan in patients with heart failure and hyponatremia
por: Oka, Tatsufumi, et al.
Publicado: (2021)

Association between Density of Coronary Artery Calcification and Serum Magnesium Levels among Patients with Chronic Kidney Disease
por: Sakaguchi, Yusuke, et al.
Publicado: (2016)

Why are mineralocorticoid receptor antagonists cardioprotective?
por: Chai, Wenxia, et al.
Publicado: (2006)

Single cell RNA sequencing uncovers cellular developmental sequences and novel potential intercellular communications in embryonic kidney
por: Matsui, Isao, et al.
Publicado: (2021)

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
por: Kolkhof, Peter, et al.
Publicado: (2017)

Quantitative Analyses of Foot Processes, Mitochondria, and Basement Membranes by Structured Illumination Microscopy Using Elastica-Masson– and Periodic-Acid-Schiff–Stained Kidney Sections
por: Matsumoto, Ayumi, et al.
Publicado: (2021)

The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic  Nephropathy
por: Goenka, Luxitaa, et al.
Publicado: (2019)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Kawanami, Daiji, et al.
Publicado: (2021)

Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone
por: Oshima, Akira, et al.
Publicado: (2021)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Vodošek Hojs, Nina, et al.
Publicado: (2021)

Mineralocorticoid receptor antagonists in cardiovascular translational biology
por: Chilton, Robert J., et al.
Publicado: (2023)

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023)

Expression of genes encoding mineralocorticoid biosynthetic enzymes and the mineralocorticoid receptor, and levels of mineralocorticoids in the bovine follicle and corpus luteum
por: MUKANGWA, Memory, et al.
Publicado: (2019)

Severe Osteomalacia with Dent Disease Caused by a Novel Intronic Mutation of the CLCN5 gene
por: Matsumoto, Ayumi, et al.
Publicado: (2018)

Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists
por: Mende, Christian W., et al.
Publicado: (2023)

Dietary casein, egg albumin, and branched-chain amino acids attenuate phosphate-induced renal tubulointerstitial injury in rats
por: Shimada, Karin, et al.
Publicado: (2020)

Hepatic phosphate uptake and subsequent nerve-mediated phosphaturia are crucial for phosphate homeostasis following portal vein passage of phosphate in rats
por: Yasuda, Seiichi, et al.
Publicado: (2023)

Effects of alfacalcidol on cardiovascular outcomes according to alkaline phosphatase levels in the J-DAVID trial
por: Oka, Tatsufumi, et al.
Publicado: (2022)

Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine
por: Funder, John W
Publicado: (2013)

Oral mineralocorticoid antagonists for recalcitrant central serous chorioretinopathy
por: Chin, Eric K, et al.
Publicado: (2015)

Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists
por: Yugar-Toledo, Juan Carlos, et al.
Publicado: (2017)

Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy
por: Sun, Li‐Jing, et al.
Publicado: (2017)

Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
por: Baran, Wiktoria, et al.
Publicado: (2021)

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
por: Shah, Monarch, et al.
Publicado: (2023)

Mineralocorticoid receptor antagonists for heart failure: a real‐life observational study
por: Bruno, Noemi, et al.
Publicado: (2018)

Red cell distribution width and renal outcome in patients with non-dialysis-dependent chronic kidney disease
por: Yonemoto, Sayoko, et al.
Publicado: (2018)

Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction
por: Suzuki, Sho, et al.
Publicado: (2020)

Effects of mineralocorticoid receptor antagonists on responses to hemorrhagic shock in rats
por: Yamamoto, Kanako, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9jucgtircc3hhebhehppqttm5b